ALPL

If you have had a routine blood test come back with a stubbornly low alkaline phosphatase, an unexplained fragility fracture, or you lost adult teeth far too early, the answer may sit inside a single gene most people have never heard of. ALPL (alkaline phosphatase, biomineralization associated) carries the instructions for an enzyme that quietly runs in the background of bone building, tooth formation, and vitamin B6 handling.

Variants in this gene cause hypophosphatasia (HPP), a condition that runs the full range from lethal infantile disease to mild adult symptoms that are routinely misdiagnosed as osteoporosis, fibromyalgia, or arthritis. Knowing your ALPL status changes which treatments are safe for you, which are dangerous, and whether your relatives should be tested too.

What ALPL Actually Does

The ALPL (alkaline phosphatase, biomineralization associated) gene codes for tissue-nonspecific alkaline phosphatase (TNAP), an enzyme that lives on the surface of cells in your bones, liver, kidneys, developing teeth, and brain blood vessels. TNAP works like a molecular pair of scissors, snipping phosphate groups off three key molecules in your body.

The most important of those molecules is inorganic pyrophosphate (PPi), a natural brake on mineral crystal formation. When TNAP clears PPi, calcium and phosphate are free to build hydroxyapatite, the mineral that makes bone and teeth hard. TNAP also activates vitamin B6 so your brain can use it, and processes a third compound called phosphoethanolamine.

Loss-of-function variants in ALPL produce too little working TNAP, so PPi piles up and blocks mineralization. The result is hypophosphatasia: a disease that softens bone, loosens teeth, and in severe pediatric cases impairs brain function because vitamin B6 cannot be properly delivered.

How Variant Severity Maps to Disease

ALPL is not an all-or-nothing gene. Different combinations of variants leave different amounts of residual enzyme activity, and that residual activity is what determines how mild or severe the disease will be.

Source: Hofmann et al., Kramer et al., Masi et al., Glotov et al.

What this means for you: a positive ALPL result is the start of a conversation, not the end of one. The same gene can produce a quiet biochemical pattern in one person and bone-softening disease in their cousin. Your specific variants, your enzyme activity, your symptoms, and your family history all need to be read together.

Bone and Dental Disease

Bone problems are the most recognizable face of hypophosphatasia. Adults with ALPL variants are more likely to have metatarsal stress fractures, femoral shaft fractures, atypical femur fractures, and persistent musculoskeletal pain. In a study of 56 adults with low TNAP, common ALPL polymorphic variants were linked to lower enzyme levels and a higher rate of metatarsal fractures.

Dental signs often arrive first. Early loss of primary teeth with the roots still attached, short-rooted permanent teeth, and abnormalities of cementum (the layer that anchors teeth in the jaw) are classic ALPL findings. A dental history of losing baby teeth too early is a red flag worth taking to a genetics workup.

There is an important management point here. Bisphosphonates and denosumab, the standard drugs used for osteoporosis, can worsen fracture risk in people with hypophosphatasia and have been linked to atypical femur fractures in ALPL variant carriers. If your bones are fragile because of an ALPL variant, treating you as if you had ordinary osteoporosis can backfire.

Vitamin B6 and Brain Effects

In severe pediatric forms of hypophosphatasia, infants can develop seizures that respond only to vitamin B6 because TNAP normally activates B6 for use in the brain. A case report of an infant with a complete loss of ALPL function described progressive brain damage, suggesting TNAP is important for normal early brain development.

In children with milder forms, a pyridoxine challenge in a study of 149 patients showed that vitamin B6 metabolism tracked clinical severity and height deficits. The takeaway for adults: high-dose B6 supplementation is not a smart move if you carry ALPL variants, because impaired processing can backfire.

Kidneys, Phosphate, and Other Body Systems

ALPL function reaches beyond bone. In a study of 129 pediatric patients with hypophosphatasia, children showed elevated blood phosphate driven by increased phosphate reabsorption in the kidneys, with low FGF7 but normal FGF23 and sFRP4 (signaling proteins that help regulate phosphate). This pattern is opposite to most kidney-related phosphate problems and is part of why HPP is so often misread.

There is also a reproductive signal. An analysis of 2,822 patients with low alkaline phosphatase found that rare ALPL variants were strongly associated with ovarian and uterine disorders in women. This is an area where evidence is still emerging, but it suggests that ALPL is not purely a bone gene.

Why So Many Adults With ALPL Variants Go Undiagnosed

Hypophosphatasia is under-recognized. In a lab cohort of 6,918 adults, about 0.52% showed biochemical signs of the disease, suggesting moderate forms are far more common than most clinicians assume. In rheumatology clinics, a study of 9,522 patients identified hypophosphatasia as a real possibility for those with unexplained musculoskeletal pain. A separate study of 713 fibromyalgia patients found that 3.2% likely had mild hypophosphatasia mislabeled as fibromyalgia.

Among adults with persistently low alkaline phosphatase, roughly half harbor an ALPL variant. The single best clue is a serum alkaline phosphatase that stays low across multiple draws, especially when combined with bone pain, fractures, dental loss, or chondrocalcinosis (calcium crystal deposits in joints).

When ALPL Testing Changes What Happens Next

A confirmed ALPL variant changes management in concrete ways. It stops well-meaning prescribers from giving you bisphosphonates or denosumab that could worsen your fractures. It opens access to enzyme replacement therapy (asfotase alfa), which in a global registry of 190 adults improved mobility, pain, and physical quality of life over three years. It tells your dentist, orthopedist, and primary care doctor to read your symptoms through a different lens.

It also rewires care for your family. ALPL is inherited, so a positive result in you flags your parents, siblings, and children as worth screening. Many will be carriers with mild biochemical signs and no symptoms, but knowing in advance lets them avoid the same diagnostic odyssey.

The Counterintuitive Part of an ALPL Result

Most disease genes feel binary in your head: you carry the variant or you do not, and a positive result means trouble. ALPL does not work that way. In a biorepository study of 37,147 people, many adults with pathogenic or likely-pathogenic ALPL variants had only low penetrance, meaning they showed mild or no symptoms. In a separate study of 43 asymptomatic carriers, biochemistry was abnormal but the people felt fine.

Read both findings together this way: ALPL is a risk-modifying gene, not a guaranteed disease sentence. A pathogenic variant raises your chance of fractures, early tooth loss, and pain, but it does not promise them. That is why ALPL testing is most useful when paired with your enzyme activity, your symptoms, and your family pattern rather than read in isolation.

Tracking Your Result Over Time

Your ALPL genotype is fixed at birth and does not change. There is no follow-up genetic test to repeat. What changes is the biochemical and clinical picture sitting on top of that genotype. Once you know your ALPL status, the right thing to retest is your serum alkaline phosphatase activity, your symptom trajectory, and your bone health markers.

For someone newly aware of an ALPL variant, a reasonable plan is to get baseline alkaline phosphatase, vitamin B6, calcium, phosphate, and bone density, then recheck the relevant labs every 6 to 12 months, more often if symptoms change. The genetic result is the anchor; the labs around it tell you whether your underlying biology is shifting.

What an Unexpected Result Should Prompt You to Do

If your test identifies a pathogenic or likely-pathogenic ALPL variant, do not wait for symptoms to act. Order a serum alkaline phosphatase, vitamin B6 (pyridoxal-5-phosphate or PLP), calcium, phosphate, and bone density. Bring the result to a metabolic bone disease specialist or endocrinologist familiar with hypophosphatasia, not just a general practitioner.

If you are currently on bisphosphonates or denosumab for presumed osteoporosis, raise the ALPL result with the prescriber before your next dose. If you have a history of unexplained fractures, dental loss, or chronic musculoskeletal pain, ask whether these now fit the pattern of mild adult hypophosphatasia. And share the result with first-degree relatives, who may want to test.

If the test identifies a variant of uncertain significance, this is genuinely an area of active reclassification. The ALPL Gene Variant Project reclassified its first 100 variants and many that were previously uncertain became pathogenic when residual activity testing was added. Stay in touch with the lab and consider rechecking the classification every couple of years.

When the Result Can Be Confusing

An ALPL genetic test reports on your DNA, which does not change. But the way it is interpreted can shift in two important ways. First, the same variant can have very different effects on different people, so two relatives with the same finding may have very different symptoms. Second, the database of known ALPL variants is still growing, so a variant called uncertain today may be reclassified as pathogenic in the next few years.